Exploring strategies for scaling up allogeneic natural killer cell therapy

“...designing a scalable, closed-system manufacturing process from the outset ensures a seamless transition from clinical to commercial scale.”

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Will Rosellini, President, CytoImmune Therapeutics, about the advancements in natural killer (NK) cell therapies for cancer and autoimmune diseases. They also discuss the role of decentralized manufacturing in improving therapy accessibility.

Please enter your email to access content Read now